MeTC7 - ≥98% , CAS No.1817841-22-7

CAS: 1817841-22-7 Cat. No.: M648616 Formula: C₃₂H₄₈BrN₃O₄ Peso molecolare: 618.65

GRADE & PURITY ≥98%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 shows good antitumor effects

In Vitro

MeTC7 (compound 5) shows potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 disrupts the VDR-Ligand-binding domain in Silico. MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line. MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 2008 cells Concentration: 250 nM Incubation Time: 18, 12 h Result: Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells. Cell Viability AssayCell Line: SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines Concentration: 0, 0.25, 0.5, 0.75, 1.0, 1.25 μM Incubation Time: 24 h Result: Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines.

In Vivo

MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 10 mg/kg Administration: IP Result: Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells. Inhibited the growth of neuroblastoma cells and Xenografts. Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.

Form:Solid

IC50& Target:IC50: 2.9 μM (VDR)

Specifications

Specifiche e purezza

≥98%

Meccanismi biochimici e fisiologici

MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 shows good antitumor effects.

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Tipo di azione

ANTAGONIST

Purezza

≥98%

Nomi e identificatori

• Peso molecolare: 618.65

Proprietà chimiche e fisiche

• Solubilità: DMSO : 16.67 mg/mL (26.95 mM; ultrasonic and warming and heat to 60°C)